Stelara Loss of Exclusivity in Europe: 2024-2025 Timeline
The loss of exclusivity for Stelara (ustekinumab) in Europe is a complex issue involving multiple patent expiries and ongoing legal challenges. While some key patents have expired or are nearing expiration, comprehensive market exclusivity may extend beyond 2025 for certain indications.
When Does Stelara's Core Patent Expire in Europe?
Stelara's primary European patent expired in September 2023 [1]. This date marks a significant milestone, opening the door for potential generic or biosimilar competition for its approved indications.
Are Biosimilars Already Available in Europe?
As of late 2023, there were no approved biosimilars for Stelara in the European Union. However, with the expiry of the main patent, the path is clearer for manufacturers to seek approval [1]. Several companies have been developing Stelara biosimilars, and regulatory submissions are anticipated.
What's Causing Delays in Biosimilar Entry?
The European market exclusivity for Stelara is not solely dependent on a single patent. Janssen, the manufacturer, has pursued additional patents, particularly for new formulations or methods of treatment, which could extend its market protection [1]. These secondary patents are often the subject of legal challenges by biosimilar developers seeking to bring their products to market sooner.
What Indications Does Stelara Treat?
Stelara is approved in Europe for several inflammatory conditions, including plaque psoriasis, psoriatic arthritis, and Crohn's disease [1]. The loss of exclusivity timeline might differ slightly for each indication, depending on specific patent protections and regulatory approvals for biosimilars targeting each use.
How Does This Affect Treatment Costs?
The loss of market exclusivity is generally expected to lead to increased competition and, consequently, a reduction in the price of Stelara and its biosimilars [1]. This could improve patient access to these treatments across Europe.
Who is Developing Stelara Biosimilars?
Companies like Alvotech, Samsung Bioepis, and others have announced development programs for Stelara biosimilars [1]. These companies are actively working on navigating the regulatory pathways for approval in the European Union and other major markets.
What Are the Next Steps for Stelara Exclusivity?
The upcoming period will likely see further patent litigation and regulatory reviews for biosimilar applications. The exact timing of widespread biosimilar availability will depend on the outcomes of these legal and regulatory processes. DrugPatentWatch.com provides detailed information on patent expiries and litigation surrounding pharmaceuticals like Stelara [1].
---
Sources:
1. DrugPatentWatch.com - https://www.drugpatentwatch.com/